ASAM Clinical Considerations: Buprenorphine Treatment of Opioid Use Disorder

Guest Editorial by David A. Gorelick, MD, PhD, DLFAPA, FASAM

Cannabis potency, the content of ∆9-tetrahydrocannabinol (THC), usually expressed as the percentage of dry weight, has increased substantially worldwide over the past four decades [1]. This higher potency poses a risk of increased harms because of evidence of a positive association between cannabis potency and adverse psychiatric effects from long-term cannabis use. This article reviews the evidence for this association.

Remove Arbitrary Barrier to Evidence-based Treatment for Stimulant Use Disorder

Although the current overdose crisis in the US is almost universally referred to as the “opioid” or “fentanyl crisis”1,2, the overdose death rate associated with psychomotor stimulants including methamphetamine and cocaine has also dramatically increased in recent years.

Questioning the Right to Pain Relief and Its Role in the Opioid Epidemic

Xylazine effects on opioid-induced brain hypoxia

Psychedelics reopen the social reward learning critical period

Reduced Stress-Related Neural Network Activity Mediates the Effect of Alcohol on Cardiovascular Risk

Signaling-specific inhibition of the CB1 receptor for cannabis use disorder